Skip to content
New: free dose calculator with 14 peptide presets. No signup.
Peptides Academy
Anamorelin
Growth-Hormone Secretagogues

Anamorelin

Pharmaceutical

Anamorelin is an orally active, small-molecule agonist of the ghrelin/growth hormone secretagogue receptor (GHSR-1a). It was developed for cancer cachexia — the loss of appetite, body weight and muscle mass that accompanies many advanced cancers. By mimicking ghrelin at its receptor, anamorelin is intended to stimulate appetite and promote gains in body weight and lean (muscle) mass. Regulatory status differs sharply by region. Anamorelin was approved in Japan on 11 December 2020 for cancer cachexia in patients with non-small cell lung cancer (NSCLC), gastric, pancreatic and colorectal cancer. In the European Union, the EMA's CHMP recommended refusing marketing authorisation for Adlumiz (anamorelin) for anorexia, cachexia or unintended weight loss in NSCLC in May 2017, confirmed that refusal on re-examination in September 2017, and the refusal was issued in November 2017. The committee judged the effect on lean body mass marginal, found no proven effect on handgrip strength or quality of life, and, after inspecting trial sites, considered safety data inadequately recorded. Anamorelin is not an FDA-approved medicine in the United States. The core evidence comes from the ROMANA 1 and ROMANA 2 phase 3 trials (979 patients with inoperable stage III/IV NSCLC and cachexia, randomised 2:1 to anamorelin 100 mg once daily or placebo for 12 weeks). Anamorelin increased lean body mass (median +0.99 kg vs −0.47 kg in ROMANA 1; +0.65 kg vs −0.98 kg in ROMANA 2) but did not improve handgrip strength. A 12-week safety extension (ROMANA 3) found adverse-event rates similar to placebo. Japanese trials reported comparable lean-mass gains in NSCLC and in gastrointestinal cancers. Anamorelin shares its target with ghrelin, the approved diagnostic agent macimorelin, the investigational prokinetic relamorelin and research secretagogues such as ibutamoren and ipamorelin. Cachexia is a serious, clinician-managed condition; standard oncology and nutritional/supportive care remain the foundation of treatment.

Specifications

Origin / ManufacturerSynthetic (orally bioavailable small-molecule GHSR-1a agonist)
Regulatory Status
Approved in Japan (December 2020) for cancer cachexiaEU marketing authorisation refused (EMA, 2017)Not FDA-approved (US)
Active Components
Anamorelin hydrochloride
StoragePer manufacturer labeling (Japan)
Shelf LifePer manufacturer labeling
Form FactorOral tablet

Clinical Evidence

ROMANA 1 and ROMANA 2 (Lancet Oncol 2016): two randomised, double-blind phase 3 trials in 979 patients with inoperable stage III/IV NSCLC and cachexia (484 and 495 patients), anamorelin 100 mg once daily vs placebo (2:1) for 12 weeks. Median lean body mass change was +0.99 kg vs −0.47 kg (ROMANA 1) and +0.65 kg vs −0.98 kg (ROMANA 2), both p<0.0001. Handgrip strength did not improve (p=0.15 and p=0.65). Grade 3–4 treatment-related adverse events did not differ; the most frequent was hyperglycaemia (<1% and 1%).

Clinical report reference

ROMANA 3 (Ann Oncol 2017): 513 patients continued anamorelin 100 mg (n=345) or placebo (n=168) for a further 12 weeks. Treatment-emergent adverse events occurred in 52.2% vs 55.7%, grade ≥3 events in 22.4% vs 21.6% and serious events in 12.8% vs 12.6%; no deaths were judged drug-related. Body-weight gains were maintained, while handgrip strength did not improve in either group.

Clinical report reference

ONO-7643-04 (Cancer 2018): randomised, double-blind trial in 174 Japanese patients with NSCLC and cachexia; lean body mass rose 1.38 kg with anamorelin 100 mg vs −0.17 kg with placebo over 12 weeks (P<.0001), with no difference in handgrip strength or 6-minute walk distance.

Clinical report reference

Gastrointestinal cancers (Cancer 2019): single-arm, open-label study in 50 Japanese patients with colorectal, gastric or pancreatic cancer cachexia; 63.3% maintained or gained lean body mass over 12 weeks (mean +1.89 kg). Adverse events occurred in 79.6%; the most common treatment-related events were raised GGT (8.2%), diabetes mellitus, hyperglycaemia and QRS prolongation (6.1% each).

Clinical report reference

Regulatory: approved in Japan on 11 December 2020 for cachexia in NSCLC, gastric, pancreatic and colorectal cancer (J Cachexia Sarcopenia Muscle 2021). EU marketing authorisation for Adlumiz was refused in 2017 after a negative CHMP opinion confirmed on re-examination (EMA).

Clinical report reference

Frequently Asked Questions

Sources & References

Every clinical claim on this page traces to a primary peer-reviewed source.

  1. 1Temel JS, Abernethy AP, Currow DC, et al.. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. The Lancet Oncology. 2016;17(4):519-531. doi:10.1016/S1470-2045(15)00558-6 PMID:26906526
  2. 2Currow D, Temel JS, Abernethy A, et al.. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Annals of Oncology. 2017;28(8):1949-1956. doi:10.1093/annonc/mdx192 PMID:28472437
  3. 3Katakami N, Uchino J, Yokoyama T, et al.. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2018;124(3):606-616. doi:10.1002/cncr.31128 PMID:29205286
  4. 4Hamauchi S, Furuse J, Takano T, et al.. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer. 2019;125(23):4294-4302. doi:10.1002/cncr.32406 PMID:31415709
  5. 5Wakabayashi H, Arai H, Inui A. The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers. Journal of Cachexia, Sarcopenia and Muscle. 2021;12(1):14-16. doi:10.1002/jcsm.12675 PMID:33382205
  6. 6European Medicines Agency. Adlumiz (anamorelin): refusal of the marketing authorisation. European Medicines Agency. 2017.

Reviewed by

Clinical Research Review Board

Pharmacology & Endocrinology Review

All clinical claims cross-checked against primary sources. Read our editorial policy →

Related Peptides

Reviewed by Clinical Research Review BoardPharmacology & Endocrinology Review

Search

Search across products, blog posts, wiki articles, and more.